🔗 Share this article

An underground market for unapproved weight-loss medications is being driven by social media fitness personalities and sellers on communication apps, based on new investigations.

Experimental Treatment Gaining Popularity Via Social Media

Retatrutide, which is still in clinical trials, is being promoted by online personalities for its supposed weight-reducing effects. Viewers are encouraged to message these accounts directly for source information, while also receiving discount codes.

Active Trade on Social Networks

Additionally, a flourishing trade exists on messaging services, where communities with thousands of members share “before and after” photos, injection guides and assertions of next-day British shipping. Vendors market the drug there before directing customers to other platforms for transactions.

Learning About Retatrutide

Retatrutide is an experimental injection developed by US drugmaker Eli Lilly. The treatment targets three gut hormones – glucagon-like peptide-1, GIP and pancreatic hormone. Preliminary studies indicate it could help patients lose up to a quarter of their total weight. Referred to as the “triple G”, the drug is being promoted online as the successor to Ozempic.

Healthcare Experts Express Concerns

Nevertheless, doctors and pharmacists have warned that the distribution of what remains an unlicensed drug in the UK is worrisome and could lead to users injecting substances of uncertain source.

Some professionals said the demand for the experimental drug could be linked to the increasing price of licensed weight loss products such as Mounjaro.

Regulatory Position and Implementation

Marketing retatrutide on social media or Telegram is prohibited in the UK, as it is an unlicensed drug that must not be marketed or distributed for personal consumption under the Human Medicines Regulations 2012.

Some influencers try to sidestep the regulations by referring to the drug as a “research chemical” or describing it as “not for human consumption”. The substance is not a controlled drug, but promotion and distribution can still breach pharmaceutical, advertising, and consumer regulations, risking fines, legal action or imprisonment.

Platform Response and Material Removal

Based on the social media company, the platform has taken down problematic material and banned related keywords and search suggestions. The organization stated it was committed to maintaining the service safe and allocating resources in strengthening enforcement strategies.

Online Marketplace Operations

Investigations also found communities with up to nine thousand members marketing retatrutide using the platform's built-in search feature, which functions like a public directory. Entering “retatrutide” instantly brings up channels with thousands of users, populated with images of weight loss, glowing reviews and step-by-step instructions for mixing or administering at residence.

Within moments of joining one community, a seller posted WhatsApp details, where most purchases occur. The seller sent an instruction manual and promised shipping within two days. When questioned whether the product was genuine, one seller said: “You can’t be sure.” Another shared a photo of a supposed testing documentation. Not one asked about body mass, health issues or past usage.

Product Information and Costs

Inside these groups, posts display black plastic packages with Royal Mail labels, stating to include fresh supplies. One communication read: “It took eight of us to load them this morning.”

Buyers can select between powder vials, mixed at residence with purified liquid, or pre-filled injectors usually priced at £160 for 20 milligrams. When asked how long a injector should last, sellers give conflicting responses ranging from a few weeks to “depends on your body”.

Service Moderation and Safety Actions

A spokesperson for the messaging service stated it regularly monitored dangerous content on its service including content that encouraged the “misuse of controlled medications”. The organization noted that it eliminated “millions of pieces of harmful content each day”.

Medical Professional Warnings

“Individuals are injecting materials they can’t verify. Although the science behind retatrutide is valid, these online versions may not contain what they claim,” said Jason Murphy, the director of pharmaceutical services at Chemist4U.

A medical professional of Asda Online Doctor connected the surge in demand to current price rises for approved weight-loss drugs such as Mounjaro. “With prices rising, individuals are turning to social media. But fake treatments are highly dangerous. You can’t be certain what’s contained or whether the conditions they were made in was sterile,” she explained.

Her staff has already encountered individuals harmed by personal administration from unconfirmed sources. “We understand the disappointment, but purchasing from messaging apps or WhatsApp is taking chances with your well-being,” stated Wyllie. “These materials could be contaminated or improperly measured.”

Producer Statement

A spokesperson from the pharmaceutical company said the substance was in third stage clinical trials and had not been evaluated or approved by any regulatory agency globally. “Consequently at this time no one can sell [it] for human use,” they said, noting that any product “falsely representing itself as a Lilly experimental substance not yet approved … may subject patients to potentially serious medical dangers”.